This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Laromustine, VNP40101M, Onrigin, NTO-1152
Description: Cloretazine is a sulfonylhydrazine alkylating agent that exerts its effects by damaging DNA. Cloretazine demonstrated a broad spectrum of anti-tumor activity in preclinical studies, including activity in selected cell lines resistant to other alkylating agents such as BCNU, cyclophosphamide and melphalan.
Deal Structure: Cloretazine was originally developed by Vion Pharmaceuticals.
In July 2011, Nanotherapeutics announced that it had acquired Cloretazine. Nanotherapeutics also acquired the U.S. and foreign patent estate covering the clinical program and announced that it will continue developing the clinical program for drug approval.
Pink Sheet Vion Cloretazine begins AML Phase III
Additional information available to subscribers only: